Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease

Nanoscope Therapeutics to Host Clinical Perspectives Panel to Discuss MCO-010 and the Treatment Landscape for Retinitis Pigmentosa and Stargardt Disease

Webcast to be held on Thursday, November 17th from 4:30-5:30 pm ET

DALLAS, TX. – November 10, 2022 – Nanoscope Therapeutics, Inc., a clinical-stage biotechnology company developing gene therapies for retinal degenerative diseases, will host a clinical perspectives event on Thursday, November 17, 2022 from 4:30 – 5:30 p.m. ET. The event will focus on Nanoscope’s lead candidate, MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic therapy, and its potential role in treating retinitis pigmentosa (RP) and Stargardt disease, two inherited retinal diseases that are leading causes of blindness in the working-age population.

Sulagna Bhattacharya, Co-Founder and CEO of Nanoscope Therapeutics, will introduce the event and provide an introduction to MCO-010. This will be followed by presentations on the treatment landscape, unmet medical need, and a Q&A panel with renowned experts in RP and Stargardt disease, including:

Stephen Tsang, M.D., Ph.D.
László Bitó Professor, Ophthalmology, Pathology and Cell Biology, Institute of Human Nutrition, and Columbia Stem Cell Initiative, Columbia University and Co-director for Stem Cells, Genome Engineering and Regenerative Medicine Course

Victor H. Gonzalez, M.D.
Founder/Chief Executive, Valley Retina Institute, McAllen, TX. Dr. Gonzalez is also affiliated with Valley Baptist Medical Center-Harlingen, South Texas Health System, Harlingen Medical Center, Mission Regional Medical Center, Rio Grande Regional Hospital, Knapp Medical Center, and Doctor’s Hospital at Renaissance.

Samar Mohanty, Ph.D., Co-Founder & President, and Aaron Osborne, MBBS, Chief Medical Officer & Chief Development Officer of Nanoscope Therapeutics will also participate in the panel discussion.

Webcast Details
A live webcast of the event will be available on the Events page of the Nanoscope Therapeutics website and may be accessed through https://nanoscope-therapeutics-conference-call.open-exchange.net/.

About Nanoscope Therapeutics Inc.
Nanoscope Therapeutics is developing gene-agnostic, sight restoring optogenetic therapies for the millions of patients blinded by retinal degenerative diseases, for which no cure exists. The company’s lead asset, MCO-010, is presently in Phase 2b multicenter, randomized, double-masked, sham-controlled clinical trials in the U.S. for retinitis pigmentosa (NCT04945772) with top line data expected Q1 2023. The company has also fully enrolled a Phase 2 trial of MCO-010 therapy in Stargardt patients (NCT05417126). MCO-010 has received FDA Fast Track designation for RP and FDA orphan drug designations for RP and Stargardt. Preclinical assets include non-viral laser delivered MCO-020 gene therapy for geographic atrophy.

Nanoscope Investor Contact:
Argot Partners
212-600-1902
Nanoscope@argotpartners.com

 

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs international conference on optogenetics. He is winner of 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.